Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$6.56 -5.2%	$5.84	$3.56 ▼ $12.92	$390.52M	0.47	229,657 shs	233,456 shs
NMRA Neumora Therapeutics	$1.56 -20.4%	$1.15	$0.61 ▼ $17.19	$317.03M	2.87	2.20 million shs	2.11 million shs
PLRX Pliant Therapeutics	$1.58 +8.2%	$1.40	$1.10 ▼ $16.10	$89.62M	1.42	1.11 million shs	1.48 million shs
VIGL Vigil Neuroscience	$8.05	$7.97	$1.31 ▼ $8.10	$383.88M	3.34	710,718 shs	2.49 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	-5.20%	-1.35%	+14.49%	+22.39%	-43.84%
NMRA Neumora Therapeutics	-20.41%	-33.62%	+99.44%	+100.98%	-87.87%
PLRX Pliant Therapeutics	+8.22%	+0.64%	+31.67%	-6.51%	-88.96%
VIGL Vigil Neuroscience	0.00%	0.00%	+0.88%	+192.73%	+93.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	2.4034 of 5 stars	3.6	2.0	0.0	3.2	1.7	0.0
NMRA Neumora Therapeutics	2.4192 of 5 stars	3.1	3.0	0.0	0.6	2.5	1.3
PLRX Pliant Therapeutics	3.6375 of 5 stars	3.0	3.0	4.7	0.6	1.7	0.6
VIGL Vigil Neuroscience	2.7973 of 5 stars	4.0	3.0	0.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.29	Buy	$29.00	342.07% Upside
NMRA Neumora Therapeutics	2.22	Hold	$7.14	357.88% Upside
PLRX Pliant Therapeutics	2.00	Hold	$13.31	742.56% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	34.16% Upside

Current Analyst Ratings Breakdown

Latest PLRX, VIGL, NMRA, and ATXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.97 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PLRX Pliant Therapeutics	$1.58M	61.39	N/A	N/A	$5.00 per share	0.32
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$1.87	N/A	N/A	N/A	N/A	-47.18%	-31.26%	8/11/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/6/2025 (Estimated)
PLRX Pliant Therapeutics	-$210.30M	-$3.61	N/A	N/A	N/A	N/A	-67.56%	-52.54%	8/6/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	8/12/2025 (Estimated)

Latest PLRX, VIGL, NMRA, and ATXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	VIGL Vigil Neuroscience	-$0.44	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ATXS Astria Therapeutics	-$0.61	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	PLRX Pliant Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	17.39	17.39
NMRA Neumora Therapeutics	N/A	8.98	8.98
PLRX Pliant Therapeutics	N/A	11.03	11.03
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
NMRA Neumora Therapeutics	47.65%
PLRX Pliant Therapeutics	97.30%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
NMRA Neumora Therapeutics	26.80%
PLRX Pliant Therapeutics	8.00%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.43 million	53.89 million	Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable
PLRX Pliant Therapeutics	90	61.39 million	56.48 million	Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable

PLRX, VIGL, NMRA, and ATXS Headlines

Recent News About These Companies

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

July 14, 2025 | businesswire.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Recommendation of "Hold" from Brokerages

July 12, 2025 | marketbeat.com

Vigil Neuroscience (NASDAQ:VIGL) Stock Price Up 0.4% - Here's What Happened

July 9, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq

June 27, 2025 | nasdaq.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

June 25, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.comB

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.comM

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.comT

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)

May 28, 2025 | msn.com

Vigil Neuroscience Analyst Ratings and Price Targets | NASDAQ:VIGL | Benzinga

May 24, 2025 | benzinga.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil ...

May 24, 2025 | morningstar.comM

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

May 24, 2025 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, VIGL, NMRA, and ATXS Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$6.56 -0.36 (-5.20%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.56 0.00 (-0.08%)

As of 08/1/2025 06:39 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Neumora Therapeutics NASDAQ:NMRA

$1.56 -0.40 (-20.41%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.64 +0.09 (+5.45%)

As of 08/1/2025 07:52 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Pliant Therapeutics NASDAQ:PLRX

$1.58 +0.12 (+8.22%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.62 +0.03 (+2.22%)

As of 08/1/2025 04:58 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$8.06 +0.01 (+0.12%)

As of 08/1/2025 05:55 PM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time